127 related articles for article (PubMed ID: 17126079)
21. Computational protein biomarker prediction: a case study for prostate cancer.
Wagner M; Naik DN; Pothen A; Kasukurti S; Devineni RR; Adam BL; Semmes OJ; Wright GL
BMC Bioinformatics; 2004 Mar; 5():26. PubMed ID: 15113409
[TBL] [Abstract][Full Text] [Related]
22. A new approach for the analysis of mass spectrometry data for biomarker discovery.
Barbarini N; Magni P; Bellazzi R
AMIA Annu Symp Proc; 2006; 2006():26-30. PubMed ID: 17238296
[TBL] [Abstract][Full Text] [Related]
23. SELDI-TOF MS versus prostate specific antigen analysis of prospective plasma samples in a nested case-control study of prostate cancer.
Skytt A; Thysell E; Stattin P; Stenman UH; Antti H; Wikström P
Int J Cancer; 2007 Aug; 121(3):615-20. PubMed ID: 17410539
[TBL] [Abstract][Full Text] [Related]
24. Analytical validation of serum proteomic profiling for diagnosis of prostate cancer: sources of sample bias.
McLerran D; Grizzle WE; Feng Z; Bigbee WL; Banez LL; Cazares LH; Chan DW; Diaz J; Izbicka E; Kagan J; Malehorn DE; Malik G; Oelschlager D; Partin A; Randolph T; Rosenzweig N; Srivastava S; Srivastava S; Thompson IM; Thornquist M; Troyer D; Yasui Y; Zhang Z; Zhu L; Semmes OJ
Clin Chem; 2008 Jan; 54(1):44-52. PubMed ID: 17981926
[TBL] [Abstract][Full Text] [Related]
25. A robust meta-classification strategy for cancer detection from MS data.
Bhanot G; Alexe G; Venkataraghavan B; Levine AJ
Proteomics; 2006 Jan; 6(2):592-604. PubMed ID: 16342141
[TBL] [Abstract][Full Text] [Related]
26. [Application of an integrated omics analysis for the discovery of biomarkers for osteosarcoma].
Li GD; Cai ZD; Ma XJ; Sun MX; Li J
Zhonghua Yi Xue Za Zhi; 2012 Jan; 92(3):192-6. PubMed ID: 22490743
[TBL] [Abstract][Full Text] [Related]
27. Feature extraction and dimensionality reduction for mass spectrometry data.
Liu Y
Comput Biol Med; 2009 Sep; 39(9):818-23. PubMed ID: 19646687
[TBL] [Abstract][Full Text] [Related]
28. Prohibitin identified by proteomic analysis of prostate biopsies distinguishes hyperplasia and cancer.
Ummanni R; Junker H; Zimmermann U; Venz S; Teller S; Giebel J; Scharf C; Woenckhaus C; Dombrowski F; Walther R
Cancer Lett; 2008 Aug; 266(2):171-85. PubMed ID: 18384941
[TBL] [Abstract][Full Text] [Related]
29. Normal, benign, preneoplastic, and malignant prostate cells have distinct protein expression profiles resolved by surface enhanced laser desorption/ionization mass spectrometry.
Cazares LH; Adam BL; Ward MD; Nasim S; Schellhammer PF; Semmes OJ; Wright GL
Clin Cancer Res; 2002 Aug; 8(8):2541-52. PubMed ID: 12171882
[TBL] [Abstract][Full Text] [Related]
30. Discovery of serum protein biomarkers for prostate cancer progression by proteomic analysis.
Al-Ruwaili JA; Larkin SE; Zeidan BA; Taylor MG; Adra CN; Aukim-Hastie CL; Townsend PA
Cancer Genomics Proteomics; 2010; 7(2):93-103. PubMed ID: 20335524
[TBL] [Abstract][Full Text] [Related]
31. The expression profile of phosphatidylinositol in high spatial resolution imaging mass spectrometry as a potential biomarker for prostate cancer.
Goto T; Terada N; Inoue T; Nakayama K; Okada Y; Yoshikawa T; Miyazaki Y; Uegaki M; Sumiyoshi S; Kobayashi T; Kamba T; Yoshimura K; Ogawa O
PLoS One; 2014; 9(2):e90242. PubMed ID: 24587297
[TBL] [Abstract][Full Text] [Related]
32. A data-mining approach to biomarker identification from protein profiles using discrete stationary wavelet transform.
Montazery-Kordy H; Miran-Baygi MH; Moradi MH
J Zhejiang Univ Sci B; 2008 Nov; 9(11):863-70. PubMed ID: 18988305
[TBL] [Abstract][Full Text] [Related]
33. Zinc α2-glycoprotein as a potential novel urine biomarker for the early diagnosis of prostate cancer.
Katafigiotis I; Tyritzis SI; Stravodimos KG; Alamanis C; Pavlakis K; Vlahou A; Makridakis M; Katafigioti A; Garbis SD; Constantinides CA
BJU Int; 2012 Dec; 110(11 Pt B):E688-93. PubMed ID: 23020913
[TBL] [Abstract][Full Text] [Related]
34. Proteomic diagnosis competition: design, concepts, participants and first results.
Mertens BJ
J Proteomics; 2009 Jul; 72(5):785-90. PubMed ID: 19375529
[TBL] [Abstract][Full Text] [Related]
35. Identification of serum biomarkers for nasopharyngeal carcinoma by proteomic analysis.
Wei YS; Zheng YH; Liang WB; Zhang JZ; Yang ZH; Lv ML; Jia J; Zhang L
Cancer; 2008 Feb; 112(3):544-51. PubMed ID: 18085639
[TBL] [Abstract][Full Text] [Related]
36. Putting the "bio" back into biomarkers: orienting proteomic discovery toward biology and away from the measurement platform.
Liotta LA; Petricoin EF
Clin Chem; 2008 Jan; 54(1):3-5. PubMed ID: 18160722
[No Abstract] [Full Text] [Related]
37. Analysis of Human Proteome Organization Plasma Proteome Project (HUPO PPP) reference specimens using surface enhanced laser desorption/ionization-time of flight (SELDI-TOF) mass spectrometry: multi-institution correlation of spectra and identification of biomarkers.
Rai AJ; Stemmer PM; Zhang Z; Adam BL; Morgan WT; Caffrey RE; Podust VN; Patel M; Lim LY; Shipulina NV; Chan DW; Semmes OJ; Leung HC
Proteomics; 2005 Aug; 5(13):3467-74. PubMed ID: 16052624
[TBL] [Abstract][Full Text] [Related]
38. Multivariate analyses for biomarkers hunting and validation through on-tissue bottom-up or in-source decay in MALDI-MSI: application to prostate cancer.
Bonnel D; Longuespee R; Franck J; Roudbaraki M; Gosset P; Day R; Salzet M; Fournier I
Anal Bioanal Chem; 2011 Jul; 401(1):149-65. PubMed ID: 21519967
[TBL] [Abstract][Full Text] [Related]
39. Detection of lung cancer using plasma protein profiling by matrix-assisted laser desorption/ionization mass spectrometry.
Shevchenko VE; Arnotskaya NE; Zaridze DG
Eur J Mass Spectrom (Chichester); 2010; 16(4):539-49. PubMed ID: 20625202
[TBL] [Abstract][Full Text] [Related]
40. Classification of cancer types by measuring variants of host response proteins using SELDI serum assays.
Fung ET; Yip TT; Lomas L; Wang Z; Yip C; Meng XY; Lin S; Zhang F; Zhang Z; Chan DW; Weinberger SR
Int J Cancer; 2005 Jul; 115(5):783-9. PubMed ID: 15704152
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
